Australia's most trusted
source of pharma news
Wednesday, 18 March 2026
Posted 18 March 2026 PM
The TGA has given a green-light to a trial for a safer CAR T-cell therapy developed by an Australian biotech and Peter Mac, with patient recruitment now expected to start this quarter.
Sydney-based HaemaLogiX's KMCAR T-cell immunotherapy is a novel autologous CAR-T cell therapy that targets Kappa Myeloma Antigen, a receptor found only on the surface of myeloma cells and not on healthy immune cells.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.